

# BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY

The 38th Annual Scientific Meeting of the British Society of Toxicological Pathology



## Preclinical translatability and pathology of cell-based therapies

Wednesday 15th – Thursday 16th November 2023

Evotec, Verona, Italy

PRELIMINARY PROGRAMME

Approved by the Royal Society of Biology for purposes of CPD, this event may be counted as 33 CPD credits.

Approximately 11.5 hours of educational activity will be recorded on Attendance Certificates.

Wednesday 15th November 2023	
08.15 - 08.45	REGISTRATION
08.45 - 09.00	WELCOME AND INTRODUCTION BY THE PRESIDENT OF THE BSTP - Catherine Ross
<b>Session 1: Advancing Cell-Based Therapies</b>	
09.00 - 09.45	<b>Cell and gene therapy: Current advances and new perspectives for cell genetic engineering</b> Prof Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy, Italy)
09.45 - 10.30	<b>Designing safer gene transfer vectors and stem cell manufacturing processes</b> Prof Fulvio Mavilio (Orchard Therapeutics, UK)
10.30 - 11.00	REFRESHMENT BREAK AND POSTER SESSION
<b>Session 2: Cell-based Therapies: Therapeutic Opportunities (I)</b>	
11.00 - 11.45	<b>Use of differentiated pluripotent stem cells as powerful and complex ATMP on the treatment of monogenic diseases</b> Dr Ana Bejanariu (Sanofi, France)
11.45 - 12.30	<b>Harnessing the power of haematopoietic stem cells: From bench to bedside</b> Prof Bernhard Genter (San Raffaele Telethon Institute for Gene T Therapy, Italy)
12.30 - 12.45	<b>Sponsor talk</b>
12.45 - 13.45	LUNCH
13.45 - 14.30	<b>Neuronal stem cell transplantation in patients with progressive multiple sclerosis</b> Prof Gianvito Martino (IRCCS San Raffaele Scientific Institute, Italy)
<b>Session 3: Modifying Lymphocytes</b>	
14.30 - 14.50	<b>T2EVOLVE: A European initiative to speed up the availability of CAR-T therapy in Europe</b> Dr Carmen Sanges (UKW, Germany)
14.50 - 15.10	<b>Profiling CAR-T cell performances in humanized mice</b> Dr Monica Casucci (IRCCS San Raffaele Scientific Institute, Italy)
15.10 - 15.30	<b>On-target Off-tumor toxicity</b> Dr Emmanuel Donnadieu (INSERM, France)
15.30 - 16.00	REFRESHMENT BREAK
16.00 - 16.30	<b>Tregs: Opportunities &amp; challenges</b> Dr Jan Klapwijk (Cornelis Consulting, UK)
16.30 - 17.00	<b>Case studies: Challenges during preclinical assessment of 2 cell-based therapies</b> Dr Deon Hildebrand (GSK, UK)
17.00 - 17.30	<b>NK cells: Development strategy and regulatory challenges</b> Dr Franck Chanut (Sanofi, France)
17.30 onwards	Canapé Reception & transfer to city centre

V: 20/09/2023

You are advised that the programme timings, lecture title and speakers may be subject to change without notice

Registered Charity No: 1043793

# BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY

The 38th Annual Scientific Meeting of the British Society of Toxicological Pathology



## Preclinical translatability and pathology of cell-based therapies

Wednesday 15th – Thursday 16th November 2023  
Evotec, Verona, Italy

PRELIMINARY PROGRAMME

Approved by the Royal Society of Biology for purposes of CPD, this event may be counted as 33 CPD credits.  
Approximately 11.5 hours of educational activity will be recorded on Attendance Certificates.

Thursday 16th November 2023	
08.15 - 08.55	REGISTRATION
08.55 - 09.00	INTRODUCTION TO DAY 2 BY THE PRESIDENT OF THE BSTP - Catherine Ross
<b>Session 4: Best Practices in Preclinical Development of Cell-based Therapy Products</b>	
09.00 - 09.45	<b>Role of pathology in regenerative solid organ cell therapy strategies</b> Dr Magnus Söderberg (AstraZeneca, Sweden)
09.45 - 10.30	 <b>IATP Maronpot Guest Lecture Award Recipient</b> <b>Preclinical strategy: Pathologist's contribution - Case histories</b> Dr Alys Bradley (Charles River Laboratories, UK)
10.30 - 11.00	REFRESHMENT BREAK AND POSTER SESSION
11.00 - 11.45	<b>Pathology of graft-host interactions</b> Dr Patrizia Cristofori (San Raffaele Telethon Institute for Gene Therapy, Italy)
<b>Session 5: Cell-based Therapies: Therapeutic Opportunities (II)</b>	
11.45 - 12.10	<b>Preclinical strategy &amp; challenges of iPSC-based cell therapeutics</b> Dr Andreas Scheel (Evotec, Germany)
12.10 - 12.35	<b>Collaboration and development of preclinical safety data for a first-in-class regenerative cell therapy for hearing loss</b> Dr Leila Abbas (RINRI Therapeutics, UK)
12.35 - 12.50	<b>Sponsor talk</b>
12.50 - 13.50	LUNCH
<b>Session 7: Regulatory Corner – an interactive case with the MHRA</b>	
13.50 - 14.50	<b>Scientific advice from MHRA - an example - Project X</b> Dr James McBlane (MHRA, UK)
<b>Session 8: Combined Medical Device &amp; Cell-based Therapies</b>	
14.50 - 15.35	<b>Challenges and opportunities in preclinical development of combined cell-based medical device products</b> Dr Pramila Singh (Charles River Laboratories, UK)
15.35 - 16.05	REFRESHMENT BREAK AND POSTER SESSION
16.05 - 16.30	<b>Cell therapy combined with a medical device to treat type 1 diabetes</b> Dr Christine Guenther (Evotec, Germany)
16.30 - 16.45	CONCLUDING REMARKS BY THE PRESIDENT OF THE BSTP – Catherine Ross

V: 20/09/2023

You are advised that the programme timings, lecture title and speakers may be subject to change without notice

Registered Charity No: 1043793